Wyeth’s Viviant Receives Second “Approvable” Letter For Osteoporosis Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests additional data on stroke and thrombotic events in the letter, Wyeth reports.
You may also be interested in...
Pfizer’s Duavee Approved For Hot Flashes, Osteoporosis Prevention
FDA cleared the single pill combining conjugated estrogens with bazedoxifene, a novel selective estrogen receptor modulator, for two indications but issued a “complete response” letter for use in vulvar and vaginal atrophy.
Wyeth’s Viviant “Approvable” For Osteoporosis
Analysis sought for treatment indication is similar to what FDA requested for prevention setting.
Wyeth’s Viviant “Approvable” For Osteoporosis
Analysis sought for treatment indication is similar to what FDA requested for prevention setting.